Browse > Article

A Case of Drug Induced Interstitial Pneumonitis by Gemcitabine  

Lee, Sung Soon (Department of Internal Medicine, Inje University, Medical School)
Ham, Cho Rom (Department of Internal Medicine, Inje University, Medical School)
Chin, Jae-Yong (Department of Internal Medicine, Inje University, Medical School)
Lee, Hye Ran (Department of Internal Medicine, Inje University, Medical School)
Kim, Su Young (Department of Radiology, Inje University, Medical School)
Kim, Mi-young (Department of Radiology, Inje University, Medical School)
Lee, Hyun-Kyung (Department of Internal Medicine, Inje University, Medical School)
Lee, Hyuk Pyo (Department of Internal Medicine, Inje University, Medical School)
Yum, Ho-Kee (Department of Internal Medicine, Inje University, Medical School)
Choi, Soo Jeon (Department of Internal Medicine, Inje University, Medical School)
Publication Information
Tuberculosis and Respiratory Diseases / v.56, no.3, 2004 , pp. 315-320 More about this Journal
Abstract
Gemcitabine is an effective newly developed chemotherapeutic agent, which is increasingly being used to treat non-small cell lung, ovarian and breast cancers. Pulmonary toxicity is usually self-limiting mild dyspnea, bronchospasm, but severe pulmonary toxicity is rarely reported. Herein, we report drug induced interstitial lung disease associated with gemcitabine treatment. High resolution computerized tomogram (HRCT) showed an increased ground glass opacity and thickened septal lines. The patient showed a rapid good response with prednisolone treatment.
Keywords
Gemcitabine; Pulmonary infiltrates; Corticosteroid therapy; Capillary leak syndrome;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Nelson R, Tarassoff P. Dyspnoea with ge mcitabine is commonly seen, often disease related, transient and rarely severe. Eur J Cancer 1995;31(A) (Suppl 5):S197-8
2 Vander Els NJ, Miller V. Successful tre atment of gemcitabine toxicity with a briefcourse of oral corticosteroid therapy. Chest 1998;114:1779-81
3 Marruchella A, Fiorenzano G, Merizzi A, Rossi S, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998;11:504-6
4 Carmichael J, Possinger K, Phillip P, Bey kirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcita bine. J Clin Oncol 1995;13:2731-6
5 Anderson BS, Luna MA, Mario A, Yee C, Hui KH, Keating MJ, et al. Fatal pulmonary failure complicating high-dose cytosine arabi noside therapy in acute leukemia. Cancer 1990;65:1079-84
6 Foucher P, Biour M, Blayac JP, Godard P, Sgro C, Kuhn M, et al. Drugs that mayinjure the respiratory system. Eur Respir J 1997;10: 265-279
7 Rosado MF, Kett DH, Schein RMH, Baraona FJ, Sridhar KS. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 2002;25:31-3
8 Boicelle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity : CT features. J Comput Assit Tomogr 2000;24:977-80
9 Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31
10 Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced nonsmall cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6
11 Haupt HM, Hutchins GM, Moore GW. Ara-C Lung: noncardiogenic pulmonary edema com plicating cytosine arabinoside therapy of leukemia. Am J Med 1981;70:256-61
12 Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from tre atment with gemcitabine. Cancer 1997;80:286-91
13 Anderson BS, Cogan BM, Keating MJ, Estey EH, McCreadie KB, Freireich EJ. Subacute pulmonary failure complicating therapy with high dose ara-C in acute leukemia. Cancer 1985;56:2181-4